Eisai and Biogen’s new anti-amyloid drug Leqembi was recently approved through the FDA’s accelerated pathway. Now, it’s on the market with a price tag … Continue reading Leqembi Clinical Trials Aren’t Over—Half of Participants Will Get the Drug for Free